ALN Reddy | Sr Vice President
Biological E Limited
Mr. Reddy is a senior leader in the biopharmaceutical and vaccine industry with more than 27 years of experience in business development, strategic alliances, and portfolio leadership. He has played a key role in building and scaling vaccine businesses by creating new growth platforms, strengthening pipelines, and enabling successful global partnerships. At Biological E Limited, he has been instrumental in shaping the company’s CDMO strategy and guiding portfolio decisions across research, clinical development, and commercialization. His work includes securing competitive R&D funding and leading the licensing of multiple vaccine programs, contributing to long-term pipeline resilience and global market access. Mr. Reddy brings a strategic, market-oriented perspective on vaccine innovation, manufacturing partnerships, and access-driven growth, making him a sought-after voice on the evolving global biopharmaceutical landscape.
Appearances:
Pre-Congress Workshops - Monday 30th March @ 10:30
GLOBAL HEALTH WORKSHOP
GLOBAL HEALTH
Room 209AB
Identifying innovative and collaborative solutions throughout the development pathway to advance Global Health vaccine candidates beyond historical roadblocks. Understanding the factors which influence access and equity in low resource settings.
10:30am Chair’s opening remarks & presentation:
Vaccine Equity—A Historical Perspective and Future Imperatives
Dr Seth Berkley, Senior Advisor, Pandemic Center at Brown University
11am Using a partnership model for peer-to-peer learning and planning to optimize vaccine impact: A case study from Hexavalent Vaccine Implementation in Africa
Dr Kate Hopkins, Senior Director of Research, Vaccine Acceptance & Delivery, Sabin Vaccine Institute
11.20am Maternal Immunization Readiness Assessment in Kenya: A Situational Analysis for RSV and GBS Vaccine IntroductionJulie Nyanchama, Kenya Medical Research Institute (KEMRI)
11:40am From Capacity to Capability: How LMIC CDMOs Are Becoming Strategic Growth Engines
ALN Reddy, Sr Vice President, Strategic Business Development, Biological E
12:00pm Enhancing Adjuvant Availability: An Open-Access Model for Global Health
Dr Gerben Marsman, Head of Alliance Management, Vaccine Formulation Institute
12:20pm Innovative Adjuvants for Global Health
Peter Tygesen, Business Development Director, SPI PharmaJuhienah Khalaf, Director of Chemistry, InImmune
12:40pm Adjuvants at Scale: Sustaining Global Demand *Title TBC
Damien Hiley, Partner & Managing Director, Desert King
GH Vaccine Development Updates:
2:00pm Development Updates for NTD VaccinesDr Maria Elena Bottazzi, Co-Director of Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine
2:20pm Early development of a blood-stage, whole parasite vaccine for malaria
Dr Michael Good, Principal Research Leader, Head, Laboratory of Vaccines for the Developing World, Griffith University
2:40pm New Tuberculosis Vaccines – update and latest developments
Prof Richard White, Prof of Infectious Disease Epidemiology, LSHTM; Co-chair, Collaboration for TB Vaccine Discovery EMTD Research Community; WHO TB Vaccine Technical Advisory Group
3:00pm Fireside chat: The 96% Solution: Transforming the Fight Against Malaria Through Unprecedented Maternal and Infant Protection
· The Global Crisis: Addressing the critical need for next-generation malaria vaccines due to increasing cases and the limitations of current solutions.
· Breakthrough Data: Unveiling the "dream come true" results showing 96% protection against clinical malaria in infants born to mothers vaccinated pre-conception.
· Maternal Immunity: Examining the implications of long-lasting, transferred maternal immunity as a game-changer for infant survival.
· Policy and Elimination: Discussion on how this high, durable efficacy impacts global health policy, funding, scalability, and the path to malaria elimination.
Moderator: Dr Stephen Hoffman, Chief Executive and Scientific Officer, Sanaria
Dr Patrick E. Duffy, Chief, Laboratory of Malaria Immunology and Vaccinology, NIAID, NIH, Bethesda, MD USA
Ambassador John Simon, Managing Partner, Total Impact Capital, Bethesda, MD, USA
3:45pm -4:45pm Panel: How Vaccine Access Differs Across Countries—and What to Do About It
· Examine how systems shape vaccine access from development to delivery.
· Contrast vaccine pathways in high- vs. low- and middle-income countries.
· Highlight barriers like trial investment gaps and delayed approvals.
· Share strategies from global experts to improve equitable access.
Moderator: Anna Larson, Advisor, Epstein Becker & Green
Rebecca Martin, President, Global Immunization, Sabin Vaccine Institute
Larry Kerr, DVP, Global Health & Multilateral Affairs, PhRMA
Chris Colwell, VP, International Government & Regulatory Affairs, USP
Dr Rajeshwari Adhiseshan, Senior Program Officer, Gates Foundation
5pm -End of Workshop
Day 2 - Wednesday 1st April @ 09:55
Panel: Chikungunya & Mosquito-Borne Vaccines: Bridging Outbreak Response, Manufacturing, and Market Creation
- li>
- Outbreak Trends: Chikungunya and mosquito-borne disease surveillance in East Africa and South Asia.
- Vaccine Development: Manufacturing, licensing, and safety insights from CEPI-funded initiatives.
- Policy Challenges: Regulatory hurdles and off-label use in outbreak response settings.
- Market Creation: Strategies for demand generation, stockpiling, and Gavi inclusion.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events